

April 26, 2012



# Oculus Innovative Sciences' Microcyn Acute Care Products Showcased at Symposium on Advanced Wound Care in Atlanta

PETALUMA, Calif., April 26, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a *commercial healthcare* company that designs, produces and markets innovative, safe and effective healthcare products in multiple markets, today provided an update related to the market activities of two of its U.S. partners.

Eloquest Healthcare, a wholly owned subsidiary of Ferndale Pharma Group, licensed the Microcyn® acute care prescription products for U.S. hospitals, ambulatory surgical and acute care centers in July 2011. Last week the company showcased its newly branded products at the Symposium on Advanced Wound Care in Atlanta, Georgia. The company intends to feature these acute care products at additional upcoming conferences.

"With help from partners like Eloquest, our current revenue run rate is greater than \$12 million, and for the first time, greater than our current operating expenses. We see a positive tipping point for Oculus coming this year, based on ramping revenues, solid margins and newly launching commercial partnerships," said Hoji Alimi, Oculus CEO and founder.

Another Oculus partner, Innovacyn Animal Health, last week announced that more than 15,000 stores in the United States and abroad now sell Vetericyn™ products. This represents a 50% increase in outlets compared to the same time period last year. Innovacyn continues to ramp its activities as the Vetericyn animal healthcare products were named "Product of the Year" in 2011 by Animal Health International, the largest distributor of animal healthcare products in the United States.

## About Oculus Innovative Sciences

Oculus Innovative Sciences is a *commercial healthcare* company that designs, produces and markets innovative, safe and effective healthcare products. Oculus is pioneering innovative solutions in multiple markets including dermatology, surgical, wound care, animal healthcare and others, and has commercialized products in the United States, Europe, India, China and Mexico and select Middle East countries. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More information can be found at [www.oculusis.com](http://www.oculusis.com).

## Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation

Reform Act of 1995, including statements about the Company's commercial and technology progress and future financial performance. These forward-looking statements are identified by the use of words such as "intends," "we see" and "continues," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the annual report on Form 10-K for the year ended March 31, 2011. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

CONTACT: Media and Investor Contact:  
Oculus Innovative Sciences, Inc.  
Dan McFadden  
Director of Public and Investor Relations  
(425) 753-2105  
[dmcfadden@oculusis.com](mailto:dmcfadden@oculusis.com)

Source: Oculus Innovative Sciences, Inc.